ClinicalTrials.gg

Desmoid Tumors clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 71 studies for Desmoid Tumors across more than 10 countries. 21 are recruiting or about to start. 48 of them are mainly about Desmoid Tumors (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09.

Status

Completed
34
Recruiting
17
Active, not recruiting
7
Status unknown
4
Withdrawn
3
Not yet recruiting
2

Phase

Phase 2
26
Phase 1
14
Phase 3
5
Phase 4
1
Early Phase 1
1

Where

United States
33
Italy
14
France
9
Canada
8
Netherlands
7
Germany
7

Who develops what

Add Desmoid Tumors to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 3 programs from 3 companies, 2 with this as their studies’ main aim; 0 with a live phase 3 study; 1 primary completion in the next 12 months.

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
Modified FOLFOX6 RegimenRecent, limited
Evidence
  • NCT05919264 · Parabilis Medicines, Inc. · Phase 2 · live · background · “mFOLFOX-6” · registered May 2023
—11 study
NivolumabRecent, limited
Evidence
  • NCT05919264 · Parabilis Medicines, Inc. · Phase 2 · live · background · “Nivolumab” · registered May 2023
Bristol-Myers Squibb76% of its industry studiesUS: Bristol-Myers Squibb (FDA 2014)EU: Bristol-Myers Squibb (EMA 2015)11 study
trifluridine tipiracil drug combinationRecent, limited
Evidence
  • NCT05919264 · Parabilis Medicines, Inc. · Phase 2 · live · background · “Trifluridine/tipiracil” · registered May 2023
Otsuka Holdings Co., Ltd.52% of its industry studies11 study

1 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 3 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 28 May 2027 est.nirogacestat · Merck KGaA, Darmstadt, Germany · Phase 2 main aimNCT07170644 A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF) — primary endpoint: Objective response rate (ORR) · 20 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Desmoid Tumors studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 1 open · SERMs 3

Coming up

8studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 8

Who these studies take

Of the 17 Desmoid Tumors studies recruiting now, 13 (76%) set no upper age limit and 4 (24%) stop at 75 or younger. 6 (35%) take children under 18. 1 (6%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 17
AgeWomenMen
104 (24%)4 (24%)
1817 (100%)16 (94%)
3016 (94%)15 (88%)
4015 (88%)14 (82%)
5014 (82%)14 (82%)
6514 (82%)14 (82%)
7513 (76%)13 (76%)
8513 (76%)13 (76%)

Across all 71 studies, recruiting or not: 23% stop at 75 or younger and 18% at 65; 41% take children; 3% are for women only and 0% for men only; 1% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 50 of 71. Browse all 71 → or search them.